– ISRAEL, Or-Yehuda – VBL Therapeutics (Nasdaq: VBLT) today announced the appointment of Marc Kozin as chairman of the board of directors as planned in October 2020 when Mr. Kozin joined the board as vice-chairman.
Dr. Bennett Shapiro, M.D., has stepped down from his chairman role but remains on the board.
“VBL has made great strides in advancing its lead asset, VB-111, in development for treatment of platinum-resistant ovarian cancer and other oncology indications,” said Mr. Kozin. “As the OVAL study nears completion with progression-free survival results expected in 2022, I am excited to lead the board toward the next phase of the company’s growth. I want to personally thank Ben for his leadership in the chairman role and for his continuing contributions to VBL.”
About VBL Therapeutics
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a publicly-traded clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for areas of unmet need in cancer and immune- or inflammatory-related indications. The VBL Therapeutics pipeline has been developed utilizing the company’s three proprietary platform technologies: a gene therapy-based platform technology targeting newly formed blood vessels, an antibody-based technology platform targeting MOSPD2, and a lecinoxoids platform comprised of a family of small-molecules. The company’s lead oncology candidate, VB-111, is an investigational, first-in-class, targeted anti-cancer gene-therapy agent in development to treat a wide range of solid tumors. VB-111 is currently being studied in phase 3 potential registration trial for platinum-resistant ovarian cancer.
For more information: https://www.vblrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
